Alzheimer's disrupts the 3D folding of DNA in brain cells

Overview

Updated 1 hour ago

Alzheimer's disease scrambles the three-dimensional folding of DNA inside brain cells, a study published in Science on July 23 reports. It's the first single-cell map of how the disease reshapes the genome's architecture across the brain.

Active and inactive regions of DNA mingle more than usual in Alzheimer's cells, and that mixing tracks with lower gene activity. The changes hit the programs that keep neurons and synapses working, while immune cells called microglia shift toward a damaged state. If the folding errors drive the disease rather than just accompany it, they open a new class of drug targets beyond plaques and tangles.

Why it matters

If genome-folding errors drive Alzheimer's rather than just accompany it, they open a new class of drug targets beyond amyloid.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

Postmortem brains mapped at single-cell resolution

10 from people with Alzheimer's, 10 without; all donors were 75 or older.

Reduced vs. increased

Short-range DNA contacts fell; long-range contacts rose

Reproducible shift in genome contact patterns across major brain cell types in Alzheimer's.

July 23, 2026

Date of Science publication

Part of a package of NIH 4D Nucleome–funded studies on genome organization.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

People Involved

Hansruedi Mathys

Senior author of the Science study; assistant professor, University of Pittsburgh School of Medicine

Leading follow-up research on genome architecture in Alzheimer's

Jian Ma

Co-led the study; professor, Ray and Stephanie Lane Computational Biology Department, Carnegie Mellon

Built the Hicformer AI model with his group

Xinyue Lu

Computational biology doctoral student, Carnegie Mellon

Co-led the research; primary builder of Hicformer

Organizations Involved

University of Pittsburgh School of Medicine

Medical school

Lead institution for the study

Mathys's lab performed single-cell mapping of brain tissue from Alzheimer's donors and matched controls.

Carnegie Mellon University

University

Developed the Hicformer AI model

Ma's group built the transformer-based model linking DNA sequence, folding, and gene expression.

National Institutes of Health

Federal agency

Funder via the 4D Nucleome program

Funded the study as part of a package of 4D Nucleome papers on genome organization in disease and aging.

Timeline

July 2026 September 2026

3 events Latest: Today

September 2026
ScienceDaily reports the discovery to a wider audience
Today Statement

The report features findings that 3D DNA organization is disrupted in several brain cell types in Alzheimer's, altering gene switching.
Today
August 2026
Carnegie Mellon details the Hicformer AI model
Statement

CMU explains how the transformer-based model links DNA sequence, folding, and gene expression to explain Alzheimer's changes.
August 2026
July 2026
Science publishes the 3D genome study
Publication

The journal publishes the Alzheimer's genome-architecture study plus a companion paper on aging, as part of NIH's 4D Nucleome program.
July 23rd, 2026

Scenarios

Study proves genome folding errors drive Alzheimer's gene changes

Possible Resolves by End of 2028

Discussed by: Study authors Hansruedi Mathys and Jian Ma; SciTech Daily coverage

The team plans functional experiments that manipulate specific folding patterns to test whether correcting them restores normal gene activity. If structural changes prove to be drivers rather than consequences of the disease, they become candidate therapeutic targets.

Genome architecture yields a new class of Alzheimer's drug targets

Unlikely Resolves by End of 2030

Discussed by: Drug Target Review; pharmaceutical researchers

Hicformer's ability to prioritize distal regulatory elements could guide drug discovery. If researchers identify gene programs whose disruption drives neurodegeneration, companies may develop candidates that restore genome organization or the gene expression it controls.

Genome organization predicts who stays sharp despite Alzheimer's pathology

Possible Resolves by Q2 2028

Discussed by: Mathys's team; cognitive resilience researchers

Some people carry Alzheimer's plaques and tangles yet remain cognitively healthy. The team wants to study whether these resilient individuals retain normal genome organization in their brain cells, which could reveal a protective mechanism.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

November 1906

Alois Alzheimer describes plaques and tangles (1906)

Alois Alzheimer presented the case of Auguste Deter, a 51-year-old woman with memory loss and confusion. He found dense deposits and tangled fibers in her brain, the plaques and tangles that still define the disease today.

Then

Emil Kraepelin named the condition Alzheimer's disease in 1910.

Now

Plaques and tangles became the organizing framework for a century of research and drug development.

Why this matters now

Like plaques in 1906, genome architecture is a newly identified biological layer. It may shift where the field looks for causes and treatments.

2001-2003

Human Genome Project draft sequence (2001-2003)

The Human Genome Project produced the complete DNA sequence, with the promise that reading genes would reveal disease causes. That promise met a wall: sequence alone didn't explain how genes were switched on and off.

Then

Researchers gained the genetic code but little understanding of its regulation in space and time.

Now

The gap pushed science toward understanding structure and regulation, setting up today's genome-folding research.

Why this matters now

The 3D genome work answers a question the sequence couldn't: how DNA bends and folds to control gene activity in brain cells.

2012-2023

Amyloid-hypothesis drugs fail in trials (2012-2023)

Decades of drug development targeting amyloid plaques produced repeated trial failures. Drugs removed plaques from the brain but did not reliably slow cognitive decline. Aducanumab (Aduhelm) won conditional approval in 2021 despite thin evidence, then was withdrawn.

Then

The approval controversy damaged confidence in the amyloid approach.

Now

The failures opened the field to other biological layers, including inflammation, metabolism, and now genome organization.

Why this matters now

Explains why a new layer of Alzheimer's biology matters here: the dominant hypothesis has not produced a cure, so researchers are hunting elsewhere.